Your Global Leader in Stem Cell Market Research
Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.
The cord blood banking industry is well-known for its shifting dynamics, including new alliances, new research advances and innovations. Every month there are major new events that affect market participants.
While it may be possible to stay informed about cord blood industry news in your region, it can be more difficult to track changes on a global scale. For that reason, the following is a summary of significant cord blood industry events for July 2015.
On June 29, 2015, AMAG Pharmaceuticals released news that reverberated throughout the cord blood banking industry worldwide, announcing that it had entered into a definitive agreement to acquire Cord Blood Registry (CBR®) for $700 million. The acquisition is expected to close during the third-quarter of 2015, based on regulatory approvals and execution of agreed upon terms and conditions.
Founded in 1992 and headquartered in San Bruno, California, Cord Blood Registry® is the largest cord blood bank in the United States and the world. CBR® currently stores over 500,000 preserved cord blood and cord tissue units, which is substantially more than its nearest competitor, ViaCord, which has approximately 350,000 units stored. [Read more…]
“Stem cell biobanking” is the cryogenic storage of stem cells, or biological samples containing stem cells, for use at a later point in time. Therefore, the “stem cell biobanking market” is defined as the total annual revenue derived from the storage of:
For company executives and investors that are competing within the stem cell biobanking marketplace, it is important to know the nine market segments that compose the stem cell biobanking market at large.
[Read more…]
For those competing within the cord blood marketplace, it is valuable to know that umbilical cord blood is the second most common source of stem cells for cellular therapy.
Because it is a rich source of highly primitive hematopoietic stem cells, umbilical cord blood has enormous regenerative potential for stem cell-based-therapy, both for the treatment of hematological and non-hematological disorders. Indeed, with the recent expansion in stem cell research and an increase in public interest in stem cell-based therapies, researchers are now exploring the potential of umbilical cord blood stem cells for non-hematological disorders.
This is evidenced by the increasing number of clinical trials that are utilizing umbilical cord blood stem cell-based therapies to treat a range of diseases.
However, with these advances come new standards that must be established, including:
Additionally, it is controversial within medical communities to use umbilical cord blood stem cells for non-hematological disorders, a perspective which is gradually starting to change. Clearly, therapeutic use of cord blood stem cells will play an important role in the future of regenerative medicine, but its applications and limitations of use have yet to be defined.
The cord blood banking industry is well-known for its shifting dynamics, including new alliances, new research advances and innovations. Every month there are major new events that affect market participants.
While it may be possible to stay informed about cord blood industry news in your region, it can be more difficult to track changes on a global scale. For that reason, the following is a summary of significant cord blood industry events for June 2015.
